Immunotherapy

Article	Citations
Imaging of brain metastases treated with immune checkpoint inhibitors	112
Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study	38
Atezolizumab and Bevacizumab prior to liver transplantation in hepatic angiosarcoma mimicking hepatocellular carcinoma	29
Cost–Effectiveness Analysis of Serplulimab as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma	28
Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer Without Tumor Pd-L1 Expression in Asia	26
Identifying risk factors and biomarkers for severe CIP in lung cancer patients– a retrospective case series study	24
Simulating a virtual tumor board with large language models: a pilot study in NSCLC patients receiving immunotherapy	23
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study	23
Disrupting neuro-immune feedback loops: novel targets to amplify cancer immunotherapy	21
Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158	20
Postvaccination immune-mediated hepatitis: what do we really know?	20
MicroRNA prognostic markers for immune checkpoint inhibitor success in urologic cancers	19
The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives	18
Therapeutic lymph node dissection with neoadjuvant immunotherapy for macroscopic melanoma – too much skin in the game?	18
Targeting PD-1/PD-L1 in Biliary Tract Cancer: Role and Available Data	18
Diagnostic and therapeutic evaluation of Blomia tropicalis in patients with allergic rhinitis	18
Pd-1, Pd-L1, Ido, Cd70 and Microsatellite Instability as Potential Targets to Prevent Immune Evasion in Sarcomas	18
Nivolumab induced discolouration of the tongue: a case report	16
Anlotinib Succeeded in Rescue Therapy For Hyperprogression Induced by Immune Checkpoint Inhibitors: A Case Report	16
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors	16
Efficacy and safety of tarlatamab, a DLL3-targeted bispecific T-cell engager, in a patient with advanced esophageal small-cell neuroendocrine carcinoma: a case report	16
Real-world data of immune-related adverse events in lung cancer patients receiving immune-checkpoint inhibitors	15
Cancer Immunotherapy Via Stem Cell-Derived NK Cells	15
What is the future of immune checkpoints inhibitors for metastatic triple negative breast cancers?	15
Cost–Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Treatment in PD-L1-Positive Metastatic Triple-Negative Breast Cancer	14

Low-Dose Metronomic Gemcitabine Pretreatments Overcome the Resistance of Breast Cancer to Immune Checkpoint Therapy	14
4-1BB Antibody Enhances Cytotoxic Activity of Natural Killer Cells Against Prostate Cancer Cells Via NKG2D Agonist Combined with IL-27	14
Adherence, persistence and treatment switching in psoriasis	14
Prognostic Value of Soluble Programmed Cell Death Ligand-1 in Patients with Non-Small-Cell Lung Cancer: A Meta-Analysis	14
Effectiveness of allergen immunotherapy with house dust mite extract for pediatric bronchial asthma	13
Durvalumab after Chemoradiotherapy in Patients with Stage III Non-Small-Cell Lung Cancer: Real-World Outcomes Versus Clinical Trial Results	13
Germinal center immune dynamics: challenges for effective vaccination in the elderly	13
Molecular Interactions of Antibodies with PD-1/PD-L1 Proteins	13
Lessons From the Diagnosis and Treatment of Severe Immune Checkpoint Inhibitor-Associated Pneumonia: A Case Report	13
Sintilimab-induced severe erosive hemorrhagic gastritis and pyloric obstruction: a case report and literature review	13
Immunotherapy expectations and knowledge in practice and clinical trials: a cross-sectional study	12
Dendritic Cell-Based Immunotherapy: A Potential Player in Oral Cancer Therapeutics	11
Emerging Advances in Nanomedicine for Breast Cancer Immunotherapy: Opportunities and Challenges	11
Liquid biopsy for guiding breast cancer immunotherapy	11
Deucravacitinib in Moderate-To-Severe Psoriasis	10
Durvalumab in Advanced Cholangiocarcinoma: Is Someone Knocking Down the Door?	10
Clinical optimization of bexmarilimab as a myeloid checkpoint therapy	10
SAFFRON-103: A Phase Ib Study of Sitravatinib Plus Tislelizumab in Anti-PD-(L)1 Refractory/Resistant Advanced Melanoma	10
Gastrointestinal toxicities associated with immune checkpoint inhibitors therapy: risks and management	10
Applications and Current Challenges of Chimeric Antigen Receptor T Cells in Treating High-Grade Gliomas in Adult and Pediatric Populations	10
Effectiveness of COVID-19 Vaccines Against Omicron Variant	10
Poor Response to Sintilimab Plus Chemotherapy in a Pulmonary Epithelioid Hemangioendothelioma Patient: A Case Report	10
Immune Checkpoint Inhibitors in Cholangiocarcinoma	10
Human Growth Hormone Supplement Promotes Human Lymphohematopoietic Cell Reconstitution in Immunodeficient Mice	10
Immune-Related Gigantomastia: A Case Study	10
Immune Checkpoint Inhibitor-Induced Autoimmune Encephalitis in Metastatic Squamous Cell Lung Cancer	9
Antithymocyte Globulin for Aplastic Anemia Secondary to Pembrolizumab: A Case Report and Review of Literature	9
Impact of Helicobacter Pylori Infection on The Efficacy of Immune Checkpoint Inhibitors for Cancer Treatment: A Meta-Analysis	9
Breaking the mold: nontraditional approaches to allergen immunotherapy for environmental allergens	9
Fulminant immune-related colitis after dual checkpoint inhibitor therapy: case report	9
Conversion surgery after pembrolizumab for initially unresectable MSI-H small bowel adenocarcinoma: a case report and brief analysis	9
Therapeutic Intervention of Glioma with the Novel Antineoplastic Agent T11TS: The Story so Far	9
Steroid-Dependent Polyarthritis Induced by Immune Checkpoint Inhibitor Therapy Successfully Treated with Bimekizumab	9
Immune Checkpoint Inhibitors in Lung Tumors with Rare Histologies and Other Thoracic Malignancies	9
Ipilimumab and Nivolumab: The ‘New Kid on the Block’ in Advanced Angiosarcoma	9
Treatment of Plaque Psoriasis with Deucravacitinib (POETYK PSO-1 Study): A Plain Language Summary	9
Integrase inhibitors: current protagonists in antiretroviral therapy	9
TOPAZ-1: A New Standard of Care for Advanced Biliary Tract Cancers?	9
Infectious Adverse Events in Patients with Atopic Dermatitis Treated with Baricitinib	9
Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis	9
A Meta-Analysis of Application of Pd-1/Pd-L1 Inhibitor-Based Immunotherapy in Unresectable Locally Advanced Triple-Negative Breast Cancer	9
Autophagy in combination therapy of temozolomide and IFN-γ in C6-induced glioblastoma: role of non-coding RNAs	8
Optimizing TIL therapy for uveal melanoma: lessons learned and unlearned from cutaneous melanoma	8
Late-Onset Toxicities of Monoclonal Antibodies in Cancer Patients	8
Cost-effectiveness of Upadacitinib vs. Tofacitinib for moderate-to-severe rheumatoid arthritis in China	8
Lebrikizumab decreases type 2 inflammatory biomarker levels in patients with asthma: data from randomized phase 3 trials (LAVOLTA I and II)	8
Abrocitinib for the Treatment of Atopic Dermatitis	8
Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis	8
Long-Term Response to Camrelizumab in a Pretreated Metastatic Mixed Testicular Germ-Cell Tumor Patient with Co-Mutations in DNA Damage-Repair Genes	8
Simultaneous Inhibition of PD-1 and LAG-3: the Future of Immunotherapy?	8

Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis	8
Upadacitinib for the Treatment of Moderate-to-Severe Crohn’s Disease	8
Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab	8
Pembrolizumab in an HIV-infected patient with glioblastoma	8
Ocular Toxicities in Chimeric Antigen Receptor T-Cell Therapy: A Real-World Study Leveraging FAERS Database	7
Evaluating the Effectiveness of the Charlson Comorbidity Index in Predicting Immune Checkpoint Inhibitor-Related Adverse Events	7
Pathological Findings Directing Immunotherapy in Renal Cell Carcinomas	7
Established and Emerging Biomarkers of Immunotherapy in Renal Cell Carcinoma	7
An Abscopal Effect in a Gastric Cancer Patient Treated with Combined Chemoimmunotherapy and Palliative Radiotherapy	7
Amlitelimab, an anti-OX40 ligand antibody, for atopic dermatitis: a plain language summary of STREAM-AD clinical study	7
Validating Khorana Risk Score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy	7
Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis	7
Indications and Effects of Biological Agents in the Treatment of Noninfectious Uveitis	7
Immunotherapies for prevention and treatment of type 1 diabetes	7
Application of immune checkpoint inhibitors in immunotherapy for gastric cancer	7
Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours	7
Treatment patterns and outcomes in melanoma brain metastasis: exploring immune-related adverse events and survival	7
Intratumoral Delivery of Immune Therapy and Gene Therapy: The Next Era for Cancer Therapy	7
Combination of Methotrexate with Oral Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Systematic Review	7
The Development of Litifilimab (BIIB 059) for Cutaneous and Systemic Lupus Erythematosus	6
Cutaneous Metastases at the Sites of Pembrolizumab-Induced Bullous Pemphigoid Lesions in a Patient with Melanoma	6
Immunotherapy of endometrial cancer: a review of recent advances	6
An Unusual Case of Immune-Related Gastritis in One Patient Receiving Toripalimab Therapy	6
Treatment of EAE Mice with Treg, G-MDSC and IL-2: a New Insight into Cell Therapy for Multiple Sclerosis	6
ICAM2 is Related to Good Prognosis in Dendritic Cell Immunotherapy for Cancer	6
Oncolytic Viruses in Lung Cancer Treatment: A Review Article	6
Moving Beyond Single-Agent Checkpoint Inhibition in Biliary Tract Cancers: What is the Next Frontier?	6
Next-generation cancer immunotherapy: the promise of CAR T-Cell therapy	6
Could senescent cells be the prescription for therapeutic cancer vaccines?	6
Fractional Exhaled Nitric Oxide in Checkpoint Inhibitor Pneumonitis: A Case Report and Literature Review	6
Mitigation strategies for gastrointestinal (GI) immune-related adverse events for patients with solid tumors receiving immunotherapy	6
Paraneoplastic dermatomyositis and Stevens-Johnson syndrome related to immunotherapy	6
A New Perspective on The Potential Application of Ripk1 in the Treatment of Sepsis	6
Neoadjuvant Immunochemotherapy in the Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: A Systematic Review	6
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations	6
Plain Language Summary of principles for improving the care of people with eosinophil-associated diseases	6
Evaluating Axatilimab as a treatment option for chronic graft-versus-host disease	6
Updated Insights on Cardiac Risks of CD19-Directed Chimeric Antigen Receptor T-cell Therapy: A Pharmacovigilance Study	6
Immunotherapeutic effects of TCL-E5 and TCL-E5-pulsed DCs: two novel HPV therapeutic vaccine candidates	6
Gamma heavy chain disease treated with daratumumab-based regimen: a first case report and review of literature	6
Sublingual immunotherapy suppresses Th2-type immune response in the allergic rhinitis mouse model by inhibiting the activation of the NFκB pathway	6
Treatment of Plaque Psoriasis with Deucravacitinib (Poetyk Pso-2 Study): A Plain Language Summary	6
Safety and Effectiveness of a 300 IR House Dust Mite Sublingual Tablet: Descriptive 4-Year Final Analysis of a Post-Marketing Surveillance in Japan	6
Summary of Certolizumab Pegol in Psoriasis Including Structural Features, Pharmacokinetics and Treatment	6
A novel dose-adjustment protocol for interrupted subcutaneous immunotherapy in children with allergic rhinitis	6
Immune checkpoint inhibitors in POLE/POLD1 proofreading-deficient CRC: from molecular basis to clinical practice and future directions	6
Allogeneic CAR-T cells for cancer immunotherapy	6
Tsunami of Immunotherapies in the Management of Esophageal Cancer	5
Plain language summary of disease activity and therapeutic response to pegcetacoplan for geographic atrophy identified by deep learning-based analysis of OCT	5
Efficacy of Long-Term Repeated Rituximab Treatment in Refractory Phospholipase A2 Receptor-Antibody-Related Membranous Nephropathy	5
Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event	5
Immune Checkpoint Inhibitors and Combinations with Other Agents in Cholangiocarcinoma	5
Immunotherapy in Atopic Dermatitis	5
Effect of Neoadjuvant Therapy on Tumor Tissue PD-L1 and VISTA Expression Levels in Non-Small-Cell Lung Cancer	5
Beyond conventional therapies: immunotherapeutic strategies targeting HPV-associated cervical cancer	5
Bimekizumab for The Treatment of Psoriasis	5
Amalgamation of Nanotechnology with Chicken IgY to Enrich Therapeutic and Diagnostic Applications: A Systematic Review	5
Pancreas-specific immune-related adverse events in patients with lung cancer: a case series study	5
Effect of Helicobacter Pylori infection on immunotherapy for gastrointestinal cancer: a narrative review	5
Radiation and Resolve: Unlocking the Synergistic Potential of Radioimmunotherapy in Advanced Lung Cancer Management	5
Immunotherapy for Head and Neck Squamous Cell Carcinoma: Current Status and Perspectives	5
Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial	5
Pharmacokinetics and Safety of CT-P17 (40 mg/0.4 ml) Versus Reference Adalimumab: Randomized Study in Healthy Japanese Adults	5
Drug evaluation: mepolizumab in chronic obstructive pulmonary disease	5
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis	5
Combination of immunotherapy and fruquintinib in metastatic colorectal cancer: the key to overcome resistance?	5
Pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction cancer: KEYNOTE-859 Q-TWiST analysis	5
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy	5
Real-World Study: Drug Reduction in Children With Allergic Rhinitis and Asthma Receiving Immunotherapy	5
A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement	5
The Use of Dostarlimab, a Safe and Efficient Monotherapy in Msi-H Rectal Cancer Patients, an Alternative to Surgery	5
Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease	5
Impact of low sodium values on survival outcomes of patients with cancer receiving immune checkpoint inhibitors	5
Friendly fire? A case of inadvertent reactivation and progression of chronic lymphocytic leukemia following the treatment of cutaneous squamous cell carcinoma with Cemiplimab – case report	5
Imaging-calculated splenic volume is associated with response in melanoma patients treated with immunotherapy	5
Oncolytic viruses in brain cancer therapy: advances, challenges, and clinical trial outcomes	5
Efficacy of first-line immune checkpoint inhibitors for recurrent/metastatic head and neck cancer: a systematic review and meta-analysis	5
Overcoming Immune-Resistance in Laryngeal Cancer: A Case Report of the Abscopal Effect and Nivolumab Beyond Progression	5
A patient empowerment program for primary immunodeficiency improves quality of life in children and adolescents	5
Cemiplimab-Induced Cytokine-Release Syndrome: Second Case Reported and Review of The Literature	5

Pegcetacoplan Treatment for Geographic Atrophy Due to Age-Related Macular Degeneration: A Plain Language Summary of the FILLY Study	5
The potential of phytomedicines to optimize CAR-T cell therapy in cancer	5
The potential of CAR T cells in autoimmune diseases	4
Enhanced Binding at Fever Temperatures of HER2 in Complex with Trastuzumab and Pertuzumab	4
Failure of immune checkpoint inhibitors for microsatellite instability-positive pancreatic adenocarcinoma with atypical pattern of short tandem repeat mutation	4
Surrogate end Points for Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Immune Checkpoint Inhibitors	4
Immunotherapy for Head and Neck Cancer: Where do We Go from Here?	4
Safety and Effectiveness of Intravenous Ct-P13 in Inflammatory Arthritis: Post-Marketing Surveillance Study in Thailand	4
Safety of Subcutaneous and Sublingual Immunotherapy with Allergoids in Children: A Real-Life Pharmacovigilance Study	4
Cost–Effectiveness Analysis of Nivolumab Plus Cabozantinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma	4
Pembrolizumab-induced myocarditis, myositis, and myasthenia gravis overlap syndrome (IM3OS) treated with Efgartigimod: case report	4
Metastatic Gastric Cancer: Synergizing and Sequencing Targeted Therapy with First-Line Immunotherapy	4
Tezepelumab for the Treatment of Severe Asthma: A Plain Language Summary of the PATHWAY and NAVIGATOR Studies	4
Could immunotherapy be a feasible treatment option for patient’s suffering from chronic epilepsy?	4
Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation	4
Satisfaction, Qol and adherence of patients allergic to dust mites and/or pollens undergoing sublingual immunotherapy	4
Immune Checkpoint Inhibitor-Related Chronic Pneumonitis: A Case Report and Literature Review	4
Plain Language Summary of the VOLTAIRE-RA in Patients with Moderate-To-Severe Rheumatoid Arthritis	4
Immunology of Osteoporosis: Relevance of Inflammatory Targets for the Development of Novel Interventions	4
Evidence for optimal treatment of immune-related adverse events needed – should we use extracorporeal photopheresis?	4
Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics	4
Ataxia Telangiectasia Mutated (ATM) gene alterations as biomarkers of response to immune checkpoint inhibitors	4
Clinical Outcomes of Immune Checkpoint Inhibitor Diabetes Mellitus at a Comprehensive Cancer Center	4
Oncolytic immunovirotherapy: finding the tumor antigen needle in the antiviral haystack	4
Cost-utility analysis of blinatumomab in pediatric patients with acute lymphoblastic leukemia in Iran	4
Evaluating stapokibart in the treatment of seasonal allergic rhinitis	4
Late-onset recurrent immune checkpoint inhibitor-related pneumonitis after cessation of pembrolizumab: a case report	4
The game changer in the cervical cancer therapeutic landscape: immunotherapy	4
Complete Response and Survival Outcomes in Patients with Advanced Cancer on Immune Checkpoint Inhibitors	4
Pembrolizumab combined with chemotherapy for advanced or metastatic non-small cell lung cancer with low PD-L1 expression: a systematic review and meta-analysis of randomized controlled trials	4
Immune checkpoint inhibitor-related colitis in a patient with non-small cell lung cancer co-infected with HBV and EBV: a case report	4
Health-related Quality of Life in Patients with Melanoma Brain Metastases Treated with Immunotherapy	4
Dual-edged therapy: corticosteroids in the era of immunotherapy	4
Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy	4
Systemic Immune–Inflammation Index Predicts Prognosis of Cancer Immunotherapy: Systemic Review and Meta-Analysis	4
Poor survival of metastatic cancer patients hospitalized due to immune checkpoint inhibitor-related adverse events	4
Multisystem immune-related adverse events during combined ipilimumab-nivolumab with subsequent disease progression: a case report	3
Albumin-myosteatosis gauge as a prognostic biomarker in patients treated with immune checkpoint inhibitors	3
Combining immunotherapy with PARP inhibitors. Is it possible to find the way through?	3
Benralizumab for the treatment of chronic spontaneous urticaria: a plain language summary of the ARROYO study	3
The Evolution of Biliary Tract Cancer: Introducing a Special Focus Issue from Immunotherapy	3
Galectin-9 and PD-L1 Antibody Blockade Combination Therapy Inhibits Tumour Progression in Pancreatic Cancer	3
Impact of antibiotics on survival outcomes and risk of gastritis/colitis in advanced-stage melanoma patients receiving immune checkpoint inhibitor therapy	3
The role of immune subtyping in glioma mRNA vaccine development	3
Prognostic value of peripheral blood neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, pan-immune-inflammation value and systemic immune-inflammation index for the efficacy of immunotherapy in p	3
Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe	3
Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis in a Patient with Chronic Lymphocytic Leukemia	3
The role of dupilumab in the treatment of eosinophilic esophagitis	3
Cost–effectiveness of Adjuvant Atezolizumab for Patients with Stage II–IIIA PD-L1+ Non-Small-Cell Lung Cancer	3
First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap	3
Efficacy of Pd-1/Pd-L1 Inhibitors in Advanced Gastroesophageal Cancer Based on Characteristics: A Meta-Analysis	3
Relatlimab and nivolumab in untreated advanced melanoma: insight into RELATIVITY	3
Adjuvant therapy in renal cell carcinoma in the immunotherapy era: where do we stand?	3
Helminth-derived biomolecules as potential therapeutics against ulcerative colitis	3
Complete pathologic response after neoadjuvant immunotherapy for mismatch repair-deficient colon cancer with invading adjacent organs	3
Treatment and Prognostic Implications of Strong PD-L1 Expression in Primary Hepatic Sarcomatoid Carcinoma	3
Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient	3
Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study	3
Penpulimab and Anlotinib in an Elderly Patient with Recurrent Cervical Cancer: A Case Report and Literature Review	3
FHL1 As a Novel Prognostic Biomarker and Correlation with Immune Infiltration Levels in Lung Adenocarcinoma	3
Comparing how Well Abrocitinib and Dupilumab Treat Atopic Dermatitis Signs and Symptoms: A Plain Language Summary	3
Development of eosinophilic esophagitis during wheat oral immunotherapy in children: a retrospective cohort analysis	3
Etrasimod for the Treatment of Ulcerative Colitis	3
Alpha/beta-defensins influence on the humoral immunity and complications in cancer of the oral cavity and oropharynx	3
Targeting CD47 Enhanced the Antitumor Immunity of PD-L1 Blockade in B-Cell Lymphoma	3
Protecting patients in the U.S. from the financial burden of cancer immunotherapy: what can be done?	3
Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma	3
How could γδ T cells change the treatment landscape for colorectal cancers?	3
IgE-mediated anaphylaxis induced by pembrolizumab	3
Janus Kinase Inhibitors: A Future All-Rounder in Axial Spondyloarthritis?	3
Efficacy of Therapies Targeting TGF-β in Solid Tumors: a Systematic Review and Meta-Analysis of Clinical Trials	3
Outcomes for Pembrolizumab Stratified by Pemetrexed Maintenance Post Pembrolizumab–Platinum–Pemetrexed Induction in Metastatic Non-Small-Cell Lung Cancer	3
Regulatory T cells in kidney transplantation: mechanisms, therapeutic advances, and future directions	3
The role of nemolizumab in the treatment of atopic dermatitis for the adult population	3
CAR-T cells for H3K27-altered diffuse midline gliomas: where do we stand?	3
Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab	3
Evaluating the efficacy and safety of tezepelumab in the treatment of chronic rhinosinusitis with nasal polyps	3
Assessing real-world treatment with SDZ ETN (an etanercept biosimilar) in people with rheumatic diseases included in the COMPACT study: a plain language summary	3
Prognostic value of serum albumin-creatinine ratio as a biomarker in patients treated with immune checkpoint inhibitors	3
Part B of the LILAC study of litifilimab for cutaneous lupus erythematosus: a plain language summary	2
Mesenchymal Stem Cell Treatment for Hyperactive Immune Response in Patients with COVID-19	2
Efficacy of PD-1/PD-L1 Plus CTLA-4 Inhibitors in Solid Tumors Based on Clinical Characteristics: a Meta-Analysis	2
Cost–effectiveness analysis of immune checkpoint inhibitors as first-line therapy in advanced biliary tract cancer	2
Reduced Risk of Infections with the Intravenous Immunoglobulin, IgPro10, in Patients at Risk of Secondary Immunodeficiency-Related Infections	2
Association of Immune-Related Adverse Events and Efficacy in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis	2
An Assessment of Extended Pembrolizumab Dosing in Advanced Non-Small-Cell Lung Cancer in the Covid-19 Pandemic	2
Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies	2
The role of exosomal PD-L1 in NSCLC immunotherapy	2
Evaluation of Appendectomy as A Potential Risk Factor for Immune Checkpoint Inhibitor-Associated Enterocolitis	2
Upadacitinib for Moderate to Severe Atopic Dermatitis	2
Feasibility Study of Novel Nanoparticles Derived from Glycyrrhizae Radix as Vaccine Adjuvant for Cancer Immunotherapy	2
Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summary	2
Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model	2
A case of immune-related adverse events, thyroid dysfunction, myocarditis with myositis, and myasthenia gravis overlap syndrome following serplulimab administration for lung adenocarcinoma	2
Absence of pre-transplant T cell response against LAA is associated with Flt3-ITD mutation and increased relapse-risk in AML patients with HSCT	2